Paola Grandi
Affiliations: | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
glioma, Oncolytic vectors, HSVGoogle:
"Paola Grandi"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Peters C, Grandi P, Nigim F. (2019) Updates on Oncolytic Virus Immunotherapy for Cancers. Molecular Therapy Oncolytics. 12: 259-262 |
| Sette P, Amankulor N, Li A, et al. (2019) GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Molecular Therapy Oncolytics. 15: 214-222 |
| Wirsching HG, Zhang H, Szulzewsky F, et al. (2019) Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. Jci Insight. 4 |
| Kennedy EM, Farkaly T, Goshert C, et al. (2018) Abstract 5929: microRNA control of an oHSV vector allows for robust oncolysis and selective control of viral replication in normal tissues Cancer Research. 78: 5929-5929 |
| Hicks A, Grandi P, Paglia M, et al. (2018) Abstract 4698: ONCR-1, a novel herpes simplex virus expressing MMP9 and ULBP3 transgenes, evokes potent oncolysis and development of antitumor immune responses Immunology |
| Wirsching H, Zhang H, Grandi P, et al. (2018) TMIC-05. ABSCOPAL IMMUNE RESPONSE IN GLIOBLASTOMA ELICITED BY MIR124-ATTENUATED ONCOLYTIC HERPES SIMPLEX VIRUS 1 ARMED WITH UL16 BINDING PROTEIN 3 Neuro-Oncology. 20: vi256-vi257 |
| Zhang X, Rao A, Sette P, et al. (2016) IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro-Oncology |
| Choudhury SR, Hudry E, Maguire CA, et al. (2016) Viral vectors for therapy of neurologic diseases. Neuropharmacology |
| Rao A, Zhang X, Deibert C, et al. (2016) Abstract 3235: IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligands Cancer Research. 76: 3235-3235 |
| Sette P, Li A, Marzulli M, et al. (2016) 520. Arming a Tumor Targeted Oncolytic HSV Vector with MMP9 for Enhanced Distribution and Killing Activity Molecular Therapy. 24: S207 |